• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·0853.HK
Share

MicroPort Scientific Corporation Stocks

HK$ 6.07Last Updated 17.09.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

HK$ 1.48B

HK$ 6.07
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

MicroPort Scientific Corp. is an investment holding company, which engages in the research and development, manufacture, and distribution of medical devices. It operates through the following segments: Cardiovascular Devices Business, Orthopedics Devices Business, Cardiac Rhythm Management Business, Endovascular and Peripheral Vascular Devices Business, Neurovascular Devices Business, Surgical Devices Business, Heart Valve Business, Surgical Robot Devices Business, and Others. The Cardiovascular Devices Business segment offers integrated medical solutions for the treatment of coronary artery-related diseases, develops, manufactures, and commercializes coronary stents and related delivery systems, along with balloon catheters, passive accessories and active devices, in fulfilling the overall demands of doctors and patients worldwide. The Orthopedics Devices Business segment is involved in the total solutions for the treatment of orthopedic problems, with an extensive range of orthopedics products that include reconstructive joints, spine and trauma products, and other professional implants and instruments. The Cardiac Rhythm Management Business segment develops, manufactures, and markets of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, with products covering pacemakers, defibrillators, and cardiac resynchronization therapy devices. The Endovascular and Peripheral Vascular Devices Business segment focuses on providing integrated disease solutions for aortic and peripheral vascular diseases such as thoracic and abdominal aortic aneurysm, aortic dissection, atherosclerosis, and lower extremity arteriosclerotic occlusion. The Neurovascular Devices Business segment specializes in providing total solutions for the treatment of neurovascular diseases, including hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke, continuously focused on research and development, production and commercialization of neurovascular therapeutic and access devices. The Surgical Devices Business segment provides overall solutions for cardiac surgery and emergency life support. The Heart Valve Business segment includes sale, manufacture, research, and development of heart valve devices. The Surgical Robot Devices Business segment designs, develops, and commercializes innovative surgical robots. The company was founded by Zhao Hua Chang in 1998 and is headquartered in Shanghai, China.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 0853.HK is 14.8 and suggests 143% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.09.2026 18:05

RBC has downgraded the ratings for LVMH and Burberry. Why don't analysts have confidence in the luxury sector?

22.09.2026 17:45

The Limits of Rationality: Why the Guru Who Predicted the Dot-Com Crash Doesn't Consider AI a Bubble

22.09.2026 17:32

Armenia could become a global AI hub. What does this mean for Central Asia?

22.09.2026 17:23

Paramount has settled its dispute with prosecutors over the Warner Bros. deal. What's next?

22.09.2026 17:00

Grail shares had their best day in 1.5 years. The regulator may approve its cancer test

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026